Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-06-13-Speech-2-252"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-06-13"^^xsd:date2
dcterms:Is Part Of	lp_eu:Question Time (Commission)2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20060613.27.2-252"2
lpv:hasSubsequent	lp_eu:2006-06-13-Speech-2-2532
lpv:speaker	lp:Sylvia-Yvonne Kaufmann2
lpv:spokenAs	substitute; LIBE (2004-07-21--2007-01-14)3 member; Temporary Committee on the alleged use of European countries by the CIA for the transport and illegal detention of prisoners (2006-01-19--2007-02-14)3 unknown; Partei des Demokratischen Sozialismus (2004-07-20--2006-10-04)3 vice-president; European Parliament (2004-07-20--2007-01-15)3 member; AFCO (2004-07-21--2007-01-14)3 member; Delegation for relations with Japan (2004-09-15--2007-03-13)3 vice-president; Parliament's Bureau (2004-07-20--2007-01-15)3 member; EUL/NGL (2004-07-20--2009-05-13)3 substitute; Delegation for relations with the Korean Peninsula (2004-09-15--2007-03-13)3
lpv:translated text	"Question No 49 by Boguslaw Sonik () In accordance with Community law, Poland recently introduced provisions authorising the parallel distribution of pharmaceuticals. Contrary to popular opinion, the price of many medicines in Poland is higher than in the 'old' Member States. Parallel distribution appears to be a good method of introducing competition in the market for proprietary products. Such competition should bring savings for the Polish Government and, at the same time, for the general public. It was recently brought to my attention that the opportunities for significant savings offered by parallel distribution in Poland cannot be fully taken advantage of owing to delivery restrictions which pharmaceutical producers have placed on wholesalers in countries with lower pharmaceutical prices. This behaviour strikes me as a flagrant breach of Community law. The Commission has recently been taking a firm stance in protecting consumer interests and ensuring competition in many sectors, including the automotive sector. So why is it being so circumspect about rigorously applying anti-monopoly provisions in the pharmaceuticals sector and protecting the interests of Polish patients?"@en1
lpv:unclassifiedMetadata	"President."1 "Subject: Parallel distribution of pharmaceuticals"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph